

Sean D Pokorney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4476210/publications.pdf>

Version: 2024-02-01

89
papers

1,643
citations

394421

19
h-index

330143

37
g-index

90
all docs

90
docs citations

90
times ranked

2945
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients'™ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015, 170, 141-148.e1.	2.7	211
2	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. <i>Lancet, The</i> , 2017, 390, 1737-1746.	13.7	154
3	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
4	Risk of atrioesophageal fistula formation with contact forceâ€“sensing catheters. <i>Heart Rhythm</i> , 2017, 14, 1328-1333.	0.7	91
5	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019, 42, 568-571.	1.8	80
6	Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads. <i>Circulation</i> , 2017, 136, 1387-1395.	1.6	58
7	Infarct healing is a dynamic process following acute myocardial infarction. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, 62.	3.3	51
8	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2433.	7.4	50
9	Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1299-1308.	2.8	42
10	Predictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 636-645.	3.2	36
11	Cable externalization and electrical failure of the Riata family of implantable cardioverter-defibrillator leads: A systematic review and meta-analysis. <i>Heart Rhythm</i> , 2015, 12, 1233-1240.	0.7	35
12	Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 661.	7.4	33
13	Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 112-120.	3.2	31
14	Sudden cardiac death after acute heart failure hospital admission: insights from ASCENDâ€“HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	7.1	29
15	Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. <i>Heart Rhythm</i> , 2016, 13, 1748-1754.	0.7	28
16	Dofetilide dose reductions and discontinuations in women compared with men. <i>Heart Rhythm</i> , 2018, 15, 478-484.	0.7	28
17	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. <i>Heart</i> , 2018, 104, 1850-1858.	2.9	23
18	Subcutaneous implantable cardioverter-defibrillator troubleshooting in patients with a left ventricular assist device: A case series and systematic review. <i>Heart Rhythm</i> , 2020, 17, 1536-1544.	0.7	21

#	ARTICLE	IF	CITATIONS
19	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. <i>Journal of the American Heart Association</i> , 2015, 4, e001573.	3.7	20
20	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1747-1755.	2.6	20
21	Novel mechanism of premature battery failure due to lithium cluster formation in implantable cardioverter-defibrillators. <i>Heart Rhythm</i> , 2014, 11, 2190-2195.	0.7	19
22	One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. <i>European Journal of Heart Failure</i> , 2020, 22, 859-867.	7.1	19
23	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 163-174.	2.1	18
24	Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 45, 111-117.	1.3	18
25	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. <i>American Heart Journal</i> , 2017, 185, 59-66.	2.7	18
26	Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation. <i>Heart</i> , 2014, 100, 1871-1877.	2.9	16
27	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. <i>Circulation</i> , 2017, 135, 38-47.	1.6	16
28	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 263-272.	4.0	16
29	Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the Implementation of a randomized controlled trial to improve treatment with oral Anticoagulants in patients with Atrial Fibrillation (IMPACT-AFib). <i>American Heart Journal</i> , 2020, 229, 110-117.	2.7	15
30	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: A systematic review. <i>International Journal of Cardiology</i> , 2014, 177, 990-994.	1.7	14
31	Catheter ablation of atrial fibrillation in cardiac amyloidosis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 913-921.	1.2	14
32	Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2199-2206.	1.7	14
33	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	2.7	11
34	Assessing generalizability of trial results in general practice. <i>European Heart Journal</i> , 2016, 37, 1154-1157.	2.2	11
35	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAPAF risk scoring systems. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1440-1447.	1.2	11
36	Catheter ablation of atrial fibrillation in patients with diabetes mellitus. <i>Heart Rhythm O2</i> , 2020, 1, 180-188.	1.7	11

#	ARTICLE	IF	CITATIONS
37	Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. <i>American Heart Journal</i> , 2020, 222, 26-29.	2.7	11
38	Temporal Trends in and Factors Associated With Use of Single Versus Dual-Coil Implantable Cardioverter-Defibrillator Leads. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 612-619.	3.2	10
39	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 756.	6.1	10
40	Electrical storm in patients with left ventricular assist devices: Risk factors, incidence, and impact on survival. <i>Heart Rhythm</i> , 2021, 18, 1263-1271.	0.7	10
41	Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?. <i>European Heart Journal</i> , 2018, 39, 1438-1441.	2.2	9
42	Healthcare Resource Use and Expenditures in Patients Newly Diagnosed With Paroxysmal Supraventricular Tachycardia. <i>American Journal of Cardiology</i> , 2020, 125, 215-221.	1.6	9
43	A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. <i>American Heart Journal</i> , 2016, 176, 107-113.	2.7	8
44	New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2485-2487.	2.8	8
45	When Less Is Not More —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2791-2793.	2.8	8
46	Stroke prevention in atrial fibrillation: Closing the gap. <i>American Heart Journal</i> , 2019, 210, 29-38.	2.7	8
47	Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. <i>Heart Rhythm</i> , 2022, 19, 1237-1244.	0.7	8
48	Ranolazine reduces atrial fibrillatory wave frequency. <i>Europace</i> , 2016, 19, euw200.	1.7	7
49	Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. <i>Journal of the American Heart Association</i> , 2020, 9, e015910.	3.7	7
50	Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 643-651.	6.1	7
51	Optimal Management of Riata Leads with No Known Electrical Abnormalities or Externalization: A Decision Analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 184-191.	1.7	6
52	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016, 134, 1122-1124.	1.6	6
53	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy. <i>Circulation</i> , 2017, 136, 1781-1783.	1.6	6
54	The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. <i>American Heart Journal</i> , 2018, 201, 17-24.	2.7	6

#	ARTICLE	IF	CITATIONS
55	Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2021, 138, 26-32.	1.6	6
56	Cost Analysis of Periprocedural Imaging in Patients Undergoing Catheter Ablation for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 114, 266-271.	1.6	5
57	Should patients on vitamin K antagonists be treated differently?. <i>European Heart Journal</i> , 2015, 36, 1431-1433.	2.2	5
58	Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). <i>American Heart Journal</i> , 2017, 192, 38-47.	2.7	5
59	Cardiovascular Implantable Electronic Device Surgery Following Left Ventricular Assist Device Implantation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1131-1139.	3.2	5
60	Preprocedural computed tomography before cardiac implanted electronic device lead extraction: Indication, technique, and approach to interpretation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 723-732.	1.7	5
61	Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. <i>American Heart Journal</i> , 2021, 233, 132-140.	2.7	5
62	Use of Implantable Cardioverter-Defibrillators Among Medicare Patientsâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1874.	7.4	4
63	Chocolate and prevention of atrial fibrillation: what is bad for the pancreas might be good for the atria?. <i>Heart</i> , 2017, 103, 1141-1142.	2.9	4
64	Lead Extraction for Cardiovascular Implantable Electronic Device Infection in Patients With Left Ventricular Assist Devices. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 672-680.	3.2	4
65	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. <i>JAMA Network Open</i> , 2022, 5, e2214321.	5.9	4
66	Hands on: How to approach patients undergoing lead extraction. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1801-1808.	1.7	3
67	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>American Heart Journal</i> , 2020, 220, 145-154.	2.7	3
68	Implantable cardioverterâ€“defibrillator lead revision following left ventricular assist device implantation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1509-1518.	1.7	3
69	Comparative outcomes of Riata and Fidelis lead management strategies: Results from the NCDRâ€“ICD Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1897-1906.	1.2	3
70	Atrial Fibrillation Complicating Acute Coronary Syndromes. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 611.	0.5	3
71	Blending Quality Improvement and Research Methods for Implementation Science, Part II. <i>AACN Advanced Critical Care</i> , 2015, 26, 366-371.	1.1	2
72	Management of Pace-Terminated Ventricular Arrhythmias. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 497-513.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Cost-Effectiveness of Left Atrial Appendage Occlusion. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	2
74	Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. <i>American Journal of Cardiology</i> , 2017, 119, 1401-1406.	1.6	2
75	Knowledge and Insights Vested in Us by the VEST. <i>Circulation</i> , 2018, 138, 2735-2737.	1.6	2
76	Continuous anticoagulation with catheter ablation: answers and questions. <i>European Heart Journal</i> , 2019, 40, 3022-3025.	2.2	2
77	Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2022, 145, 1705-1707.	1.6	2
78	Effect of Amiodarone-Induced Hyperthyroidism on Left Ventricular Outflow Obstruction After Septal Myectomy for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2010, 106, 1670-1672.	1.6	1
79	Practical advice on safe and effective use of non-vitamin K antagonist oral anticoagulants. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 146-147.	3.0	1
80	Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices. <i>JACC: Heart Failure</i> , 2017, 5, 927-929.	4.1	1
81	Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1706-1708.	2.2	1
82	VVI pacing with normal QRS duration and ventricular function: MOST trial findings relevant to leadless pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1461-1466.	1.2	1
83	Warfarin for Atrial Fibrillation Stroke Prophylaxis in Advanced Kidney Disease. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1669-1671.	3.2	1
84	Treatment of atrial fibrillation: is it as easy as A-B-C?. <i>Europace</i> , 2021, 23, 161-162.	1.7	1
85	AORTIC VALVE ENDOCARDITIS AS A COMPLICATION OF TOCILIZUMAB TREATMENT IN COVID 19 PATIENT. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3002.	2.8	1
86	Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. <i>AACN Advanced Critical Care</i> , 2015, 26, 366-371.	1.1	1
87	Calcified Pipes. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	2.6	0
88	Challenges in atrial fibrillation beyond stroke prevention: keeping patients out of the hospital. <i>Europace</i> , 2016, 18, 1117-1118.	1.7	0
89	Author's Reply Hemodynamic collapse following protamine sulfate: The impact of acute pulmonary vasoconstriction. <i>Heart Rhythm Case Reports</i> , 2020, 6, 547.	0.4	0